NCT01292707

Brief Summary

Background. Overdiagnosis of malaria is widespread in health facilities throughout Africa, a situation that is unsustainable given the relatively high cost of artemisinin combination therapy (ACTs) compared to older antimalarials. In addition it often denies patients treatment for their actual illness and generates unreliable data for health planners. For these reasons the National Malaria Control Programme introduced revised guidelines for malaria diagnosis and treatment in 2006 restricting the recommendation for antimalarial treatment in patients over the age of 5 years to those with a positive blood slide or malaria rapid diagnostic tests (RDTs) result. To support this, RDTs will be introduced into primary care health facilities in Tanzania starting in 2009. The high accuracy of current rapid diagnostic tests (RDTs) provides the potential for a cost-effective solution to the problem of malaria overdiagnosis. However, RDTs with revised guidelines to restrict malaria diagnoses to RDT-positive patients have been unsuccessful unless accompanied by unsustainable levels of supervision and training. Primary objective. To conduct a trial of interventions directed at prescribers or prescribers and communities compared to control groups to improve adherence to national guidelines for prescription of antimalarial treatment when supported by RDTs in primary health care facilities in NE Tanzania. Methods All 60 participating health facilities will receive RDTs and basic training in their use and a copy of current NMCP/MOH guidelines for each prescribing staff member. A health worker intervention arm will, in addition, receive workplace-based interactive training and messages from senior staff A health worker-community arm will receive the same training as the health worker arm and in addition leaflets will be provided to RDT-tested patients providing information on the test and the treatment given. All training materials will be approved by NMCP in Tanzania as being consistent with current national guidelines but with the addition that prescribers will be asked to follow RDT results in prescribing for patients of any age This policy is in line with the most recent revision to WHO guidelines and is supported by NMCP in Tanzania. Study outcomes will be recorded through a 40% (2 days per week) exit survey of patients. Anthropological and economics studies will assess the costs and acceptability of interventions.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,152

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 28, 2011

Completed
4 days until next milestone

Study Start

First participant enrolled

February 1, 2011

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 9, 2011

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2012

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2012

Completed
Last Updated

November 19, 2014

Status Verified

November 1, 2014

Enrollment Period

1 year

First QC Date

January 28, 2011

Last Update Submit

November 18, 2014

Conditions

Keywords

malariardtfevertreatment

Outcome Measures

Primary Outcomes (1)

  • The proportion of patients with a non-severe non-malarial illness prescribed a recommended antimalarial drug in a new consultation.

    1year

Study Arms (3)

Control

ACTIVE COMPARATOR

Prescribing staff in control facilities will receive the standard package of RDT training that is being provided by NMCP in Tanzania

Behavioral: Control

HW

ACTIVE COMPARATOR

Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial.

Behavioral: HW

HWC

ACTIVE COMPARATOR

The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.

Behavioral: HWC

Interventions

ControlBEHAVIORAL

Standard national training

Control
HWBEHAVIORAL

Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial

HW
HWCBEHAVIORAL

The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.

HWC

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Located in lowland Muheza, adjoining wards of Handeni, or any area of Moshi Rural Districts
  • Health facilities that are registered with the District Health Authority
  • Receives Government supplies of ALu and qualifies for RDT supply
  • Agrees to exclusive use of RDT for routine diagnosis of first consultations for possible malaria
  • Accessible by 4-wd vehicle throughout the year.
  • Availability of data on proportion of consultations diagnosed with malaria in 2008 (or earliest available year)

You may not qualify if:

  • Presence of other research in the immediate area where study procedures could bias outcomes in either study.
  • Fewer than 500 cases per year were reported in 2005 or 2006.
  • All patients with non-severe illness in first consultations.
  • Patients who have been referred to the next level of care
  • Patient refuses consent to exit survey
  • Follow-up consultations

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Joint Malaria Programme

Moshi, Kilimanjaro, Tanzania

Location

Related Publications (3)

  • Leurent B, Reyburn H, Muro F, Mbakilwa H, Schellenberg D. Monitoring patient care through health facility exit interviews: an assessment of the Hawthorne effect in a trial of adherence to malaria treatment guidelines in Tanzania. BMC Infect Dis. 2016 Feb 3;16:59. doi: 10.1186/s12879-016-1362-0.

  • Cundill B, Mbakilwa H, Chandler CI, Mtove G, Mtei F, Willetts A, Foster E, Muro F, Mwinyishehe R, Mandike R, Olomi R, Whitty CJ, Reyburn H. Prescriber and patient-oriented behavioural interventions to improve use of malaria rapid diagnostic tests in Tanzania: facility-based cluster randomised trial. BMC Med. 2015 May 15;13:118. doi: 10.1186/s12916-015-0346-z.

  • Chandler CI, Meta J, Ponzo C, Nasuwa F, Kessy J, Mbakilwa H, Haaland A, Reyburn H. The development of effective behaviour change interventions to support the use of malaria rapid diagnostic tests by Tanzanian clinicians. Implement Sci. 2014 Jun 26;9:83. doi: 10.1186/1748-5908-9-83.

MeSH Terms

Conditions

MalariaRhabdoid TumorFever

Condition Hierarchy (Ancestors)

Protozoan InfectionsParasitic DiseasesInfectionsMosquito-Borne DiseasesVector Borne DiseasesNeoplasms, Complex and MixedNeoplasms by Histologic TypeNeoplasmsBody Temperature ChangesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Hugh Reyburn, MD

    London School of Hygiene and Tropical Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 28, 2011

First Posted

February 9, 2011

Study Start

February 1, 2011

Primary Completion

February 1, 2012

Study Completion

April 1, 2012

Last Updated

November 19, 2014

Record last verified: 2014-11

Locations